Literature DB >> 10992493

Genetic immunization of BALB/c mice with a plasmid bearing the gene coding for a hybrid merozoite surface protein 1-hepatitis B virus surface protein fusion protects mice against lethal Plasmodium chabaudi chabaudi PC1 infection.

G Wunderlich1, I C Moura, H A del Portillo.   

Abstract

The genetic immunization of rodents with a plasmid coding for a Plasmodium chabaudi merozoite surface protein 1 (C terminus)-hepatitis B virus surface fusion protein (pPcMSP1(19)-HBs) provided protection of mice against subsequent lethal challenge with P. chabaudi chabaudi PC1-infected red blood cells. The percentage of survivor mice was higher in DNA-immunized mice than in animals immunized with a recombinant rPcMSP1(19)- glutathione S-transferase fusion protein administered in Freund adjuvant. In all mice immunized with the pPcMSP1(19)-HBs, a Th1-specific response, including the production of anti-MSP1(19)-specific immunoglobulins predominantly of the immunoglobulin G2a subtype and reacting almost exclusively against discontinuous epitopes, was elicited. The coinjection of Th1-type cytokine-expressing plasmids (gamma interferon, interleukin-2, and granulocyte-macrophage colony-stimulating factor) mostly abolished protection and boosting of MSP1(19)-specific antibodies. The inclusion of a lymph node-targeting signal did not significantly increase protection. These data provide further evidence that MSP1(19)-HBs DNA constructs might be useful as components of a genetic vaccine against the asexual blood stages of Plasmodium.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10992493      PMCID: PMC101545          DOI: 10.1128/IAI.68.10.5839-5845.2000

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  30 in total

1.  A universal T cell epitope-containing peptide from hepatitis B surface antigen can enhance antibody specific for HIV gp120.

Authors:  J L Greenstein; V C Schad; W H Goodwin; A B Brauer; B K Bollinger; R D Chin; M C Kuo
Journal:  J Immunol       Date:  1992-06-15       Impact factor: 5.422

2.  Comparison of humoral immune responses elicited by DNA and protein vaccines based on merozoite surface protein-1 from Plasmodium yoelii, a rodent malaria parasite.

Authors:  Y Kang; P A Calvo; T M Daly; C A Long
Journal:  J Immunol       Date:  1998-10-15       Impact factor: 5.422

3.  Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction.

Authors:  J S Boyle; J L Brady; A M Lew
Journal:  Nature       Date:  1998-03-26       Impact factor: 49.962

4.  Biochemical and immunological properties of a viral hybrid particle expressing the Plasmodium vivax merozoite surface protein 1 C-terminal region.

Authors:  G Wunderlich; H A del Portillo
Journal:  Mol Med       Date:  2000-03       Impact factor: 6.354

5.  Immunostimulatory DNA sequences necessary for effective intradermal gene immunization.

Authors:  Y Sato; M Roman; H Tighe; D Lee; M Corr; M D Nguyen; G J Silverman; M Lotz; D A Carson; E Raz
Journal:  Science       Date:  1996-07-19       Impact factor: 47.728

6.  In vivo treatment with interleukin 2 reduces parasitemia and restores IFN-gamma gene expression and T-cell proliferation during acute murine malaria.

Authors:  B Lucas; L H Kasper; K Smith; A Haque
Journal:  C R Acad Sci III       Date:  1996-08

7.  Manipulation of the immune response to a plasmid-encoded viral antigen by coinoculation with plasmids expressing cytokines.

Authors:  Z Xiang; H C Ertl
Journal:  Immunity       Date:  1995-02       Impact factor: 31.745

8.  A recombinant baculovirus 42-kilodalton C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 protects Aotus monkeys against malaria.

Authors:  S P Chang; S E Case; W L Gosnell; A Hashimoto; K J Kramer; L Q Tam; C Q Hashiro; C M Nikaido; H L Gibson; C T Lee-Ng; P J Barr; B T Yokota; G S Hut
Journal:  Infect Immun       Date:  1996-01       Impact factor: 3.441

9.  Humoral response to a carboxyl-terminal region of the merozoite surface protein-1 plays a predominant role in controlling blood-stage infection in rodent malaria.

Authors:  T M Daly; C A Long
Journal:  J Immunol       Date:  1995-07-01       Impact factor: 5.422

10.  Linkage of exogenous T-cell epitopes to the 19-kilodalton region of Plasmodium yoelii merozoite surface protein 1 (MSP1(19)) can enhance protective immunity against malaria and modulate the immunoglobulin subclass response to MSP1(19).

Authors:  N Ahlborg; I T Ling; A A Holder; E M Riley
Journal:  Infect Immun       Date:  2000-04       Impact factor: 3.441

View more
  7 in total

1.  Construction and identification of Complex DNA vaccine of hepatitis B and Toxoplasma gondii.

Authors:  Qing-Kuan Wei; Ting Xiao; Jin Li; Kun Yin; Feng-Ju Jia; Chao Xu; Gui-Hua Zhao; Yong Cui; Gong-Zhen Liu; Hui Sun; Hong-Tao Jiang; Ge Yan; Bing-Cheng Huang
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Viral vectored granulocyte-macrophage colony stimulating factor inhibits vaccine protection in an SIV challenge model: protection correlates with neutralizing antibody.

Authors:  John B Schell; Kapil Bahl; Nina F Rose; Linda Buonocore; Meredith Hunter; Preston A Marx; Celia C LaBranche; David C Montefiori; John K Rose
Journal:  Vaccine       Date:  2012-04-23       Impact factor: 3.641

3.  Genetic linkage of autologous T cell epitopes in a chimeric recombinant construct improves anti-parasite and anti-disease protective effect of a malaria vaccine candidate.

Authors:  Balwan Singh; Monica Cabrera-Mora; Jianlin Jiang; Mary Galinski; Alberto Moreno
Journal:  Vaccine       Date:  2010-01-22       Impact factor: 3.641

4.  A fusion DNA vaccine encoding middle version of HBV envelope protein fused to interleukin-21 did not enhance HBV-specific immune response in mice.

Authors:  Ye Zhang; Wen-Jing Su; Jue Wang; Xue-Fan Bai; Chang-Xing Huang; Jian-Qi Lian
Journal:  Viral Immunol       Date:  2014-09-11       Impact factor: 2.257

5.  Immunogenicity of hybrid DNA vaccines expressing hepatitis B core particles carrying human and simian immunodeficiency virus epitopes in mice and rhesus macaques.

Authors:  Deborah Heydenburg Fuller; Tim Shipley; Todd M Allen; James T Fuller; Mary S Wu; Helen Horton; Nancy Wilson; Georg Widera; David I Watkins
Journal:  Virology       Date:  2007-04-11       Impact factor: 3.616

6.  DNA-Loaded Cationic Liposomes Efficiently Function as a Vaccine against Malarial Proteins.

Authors:  Wesley L Fotoran; Rachele Santangelo; Beatriz N M de Miranda; Darrell J Irvine; Gerhard Wunderlich
Journal:  Mol Ther Methods Clin Dev       Date:  2017-08-23       Impact factor: 6.698

7.  Clinical trial in healthy malaria-naïve adults to evaluate the safety, tolerability, immunogenicity and efficacy of MuStDO5, a five-gene, sporozoite/hepatic stage Plasmodium falciparum DNA vaccine combined with escalating dose human GM-CSF DNA.

Authors:  Thomas L Richie; Yupin Charoenvit; Ruobing Wang; Judith E Epstein; Richard C Hedstrom; Sanjai Kumar; Thomas C Luke; Daniel A Freilich; Joao C Aguiar; John B Sacci; Martha Sedegah; Ronald A Nosek; Patricia De La Vega; Mara P Berzins; Victoria F Majam; Esteban N Abot; Harini Ganeshan; Nancy O Richie; Jo Glenna Banania; Maria Fe B Baraceros; Tanya G Geter; Robin Mere; Lolita Bebris; Keith Limbach; Bradley W Hickey; David E Lanar; Jennifer Ng; Meng Shi; Peter M Hobart; Jon A Norman; Lorraine A Soisson; Michael R Hollingdale; William O Rogers; Denise L Doolan; Stephen L Hoffman
Journal:  Hum Vaccin Immunother       Date:  2012-11-01       Impact factor: 3.452

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.